Exchange: NASDAQ·Updated 07:41 PM EST

ZURA News

News
all
press releases
Zura Bio (NASDAQ:ZURA) Stock Rating Lowered by Wall Street Zen
Wall Street Zen downgraded shares of Zura Bio from a "sell" rating to a "strong sell" rating in a report on Saturday...
MarketBeat
Zura Bio (NASDAQ:ZURA) Stock Rating Lowered by Wall Street Zen
Wall Street Zen downgraded shares of Zura Bio from a "sell" rating to a "strong sell" rating in a report on Saturday...
MarketBeat
More News
Zura Bio Limited (ZURA) Securities Investigation Notice - Levi & Korsinsky Zura Bio Limited (ZURA) Securities Investigation Notice - Levi & KorsinskyPR NewswireNEW YORK, Nov. 16, 2026 ZURA shareholders saw their shares decline approximately 72% at market open after the Company disclosed that its...
PR Newswire
Zura Bio: A 70% Collapse Doesn't Mean The Science Is Dead...
SeekingAlpha
ZURA SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Zura Bio Limited ZURA SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Zura Bio LimitedPR NewswireNEW YORK, Nov. 10, 2026 Whether they sold following...
PR Newswire
Zura Bio Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Zura Bio Limited (ZURA) Zura Bio Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Zura Bio Limited (ZURA)PR NewswireNEW YORK, Nov. 9, 2026 Zura Bio's October 27...
PR Newswire
Zura Bio Limited (Nasdaq: ZURA) (Zura), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today announced that its Phase 2 TibuSHIELD study, which...
Business Wire
Zura Bio Limited (Nasdaq: ZURA) (Zura or the Company), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today reported that on October 26, 2026, the...
Business Wire
Zura Bio Limited (Nasdaq: ZURA) (Zura), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today announced financial results for the third quarter...
Business Wire
Zura Bio Limited (Nasdaq: ZURA) (Zura), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today announced that members of its management team will...
Business Wire
Zura Bio Limited (Nasdaq: ZURA) (Zura or the Company), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today reported that on August 20, 2026, the...
Business Wire

Advertisement|Remove ads.